Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
SAN DIEGO, October 8 /PRNewswire/ --
- Findings Confirm Potency of Poly-ICR as Vaccine Adjuvant
Nventa Biopharmaceuticals Corporation (TSX: NVN) today presented positive data from preclinical…